Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05990608
Other study ID # 2021/371
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 30, 2021
Est. completion date July 30, 2023

Study information

Verified date August 2023
Source Ondokuz Mayis University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To perform the reliability and validity study of the Peabody Developmental Motor Scale (Peabody Developmental Motor Scales-2) in children with Duchenne Muscular Dystrophy (DMD).


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date July 30, 2023
Est. primary completion date July 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 5 Years
Eligibility Inclusion Criteria: - for Group I: - No neurodevelopmental problems or diseases - 3-5 years old - Being able to cooperate with the instructions given by the physiotherapist. - Children who volunteered to participate in the study and whose families gave consent form will be included in the study. - for Group II: - Being diagnosed with Duchenne Muscular Dystrophy by a pediatric neurologist - 3-5 years old - Children who volunteered to participate in the study and whose parents' consent was obtained will be included in the study. Exclusion Criteria: - Children with a behavioral condition and any disorder that interferes with testing (eg autism spectrum disorder) - Failure to cooperate with the physiotherapist who made the evaluations. - Lack of volunteers.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Peabody Developmental Motor Scales-2, PDMS
The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as "very low, low, below average, above average, high, very high".

Locations

Country Name City State
Turkey Ondokuz Mayis University Samsun

Sponsors (1)

Lead Sponsor Collaborator
Ondokuz Mayis University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peabody Developmental Motor Scales-2 This assessment will take place over the course of the study started and to the finish time
See also
  Status Clinical Trial Phase
Terminated NCT02814019 - A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Phase 3
Completed NCT01478022 - To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 Phase 1
Completed NCT00654784 - Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy Phase 2
Recruiting NCT02614820 - The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD N/A
Withdrawn NCT02036463 - A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy Phase 2
Completed NCT02255552 - Study of Eteplirsen in DMD Patients Phase 3
Completed NCT01982695 - Cardiomyopathy in DMD: Lisinopril vs. Losartan N/A
Recruiting NCT05516745 - E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home" N/A
Completed NCT02420379 - Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Phase 2
Active, not recruiting NCT05135663 - Extension Study of NS-089/NCNP-02 in DMD Phase 2
Completed NCT01380964 - Research of Biomarkers in Duchenne Muscular Dystrophy Patients N/A
Recruiting NCT04322357 - Twice Weekly Steroids and Exercise as Therapy for DMD Phase 2
Not yet recruiting NCT06392724 - A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy. Early Phase 1
Completed NCT01540409 - Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Phase 2
Terminated NCT04184882 - A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) Phase 1
Terminated NCT04254172 - A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
Recruiting NCT05524883 - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Phase 1/Phase 2
Completed NCT01761292 - A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Phase 1/Phase 2